{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-22-000108","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.663756+00:00","generated_at":"2026-06-21T07:43:35.858557+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Context reports preliminary Phase 2 data for ONA-XR: 4-month PFS rate of 44% in metastatic breast cancer","bullets":["4-month progression-free survival (PFS) rate of 44% in ER+, HER2- metastatic breast cancer patients in SMILE trial.","ONA-XR combined with fulvestrant showed favorable safety and tolerability in second- or third-line setting.","Previously disclosed endometrial cancer data showed 4-month PFS rate of 77% with anastrozole combination.","ELONA Phase 1b/2 trial combining ONA-XR with elacestrant; Phase 1b data expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-22-000108","json":"https://secwatch.observer/filing/0001842952-22-000108.json","markdown":"https://secwatch.observer/filing/0001842952-22-000108.md","text":"https://secwatch.observer/filing/0001842952-22-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000108/0001842952-22-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000108/cntx-20221207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:43:35.858557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}